Trospium Chloride XR in Obese Female Patients With Overactive Bladder

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Trospium chloride

Criteria

Inclusion Criteria:

• OAB syndrome with Urgency, Urinary frequency and Urgency urinary incontinence

• Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).

• Obese

Exclusion Criteria:

• Chronic kidney failure

• Abdominal bypass surgery for obesity

• Moderate or severe memory impairment

• Uncontrolled narrow angle glaucoma

• Uncontrolled systemic disease

• Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia